These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
497 related items for PubMed ID: 27792717
21. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Moskowitz CH, Glassman JR, Wuest D, Maslak P, Reich L, Gucciardo A, Coady-Lyons N, Zelenetz AD, Nimer SD. Clin Cancer Res; 1998 Feb; 4(2):311-6. PubMed ID: 9516916 [Abstract] [Full Text] [Related]
22. Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Schmitz N, Dreger P, Zander AR, Ehninger G, Wandt H, Fauser AA, Kolb HJ, Zumsprekel A, Martin A, Hecht T. Bone Marrow Transplant; 1995 Feb; 15(2):261-6. PubMed ID: 7539668 [Abstract] [Full Text] [Related]
23. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients. Todisco E, Castagna L, Sarina B, Mazza R, Magagnoli M, Balzarotti M, Nozza A, Siracusano L, Timofeeva I, Anastasia A, Demarco M, Santoro A. Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558 [Abstract] [Full Text] [Related]
24. Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients. Martino M, Recchia AG, Moscato T, Fedele R, Neri S, Gentile M, Alati C, Vincelli ID, Piro E, Penna G, Musolino C, Ronco F, Molica S, Morabito F. Cytotherapy; 2015 Oct; 17(10):1485-93. PubMed ID: 26188967 [Abstract] [Full Text] [Related]
25. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis. Kanteti R, Miller K, McCann J, Roitman D, Morelli J, Hurley C, Berkman E, Schenkein D. Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930 [Abstract] [Full Text] [Related]
26. Biosimilar filgrastim (leucostim®) have similar efficacy in steady-state hematopoietic progenitor cell mobilization compared to original filgrastim (neupogen®) and lenograstim (granocyte®): A retrospective multicenter study. Kayıkçı Ö, Tekgündüz E, Kaya AH, Göker H, Aslan A, İskender D, Namdaroglu S, Tetik A, Koçubaba Ş, Altuntaş F. Transfus Apher Sci; 2017 Dec; 56(6):832-835. PubMed ID: 29162397 [Abstract] [Full Text] [Related]
27. Timing of platelet recovery is associated with adequacy of leukapheresis product yield after cyclophosphamide and G-CSF in patients with lymphoma. Zimmerman TM, Michelson GC, Mick R, Grinblatt DL, Williams SF. J Clin Apher; 1999 Dec; 14(1):31-4. PubMed ID: 10355661 [Abstract] [Full Text] [Related]
28. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation. Wang S, Nademanee A, Qian D, Dagis A, Park HS, Fridey J, Smith E, Snyder D, Somlo G, Stein A, Rosenthal J, Falk P, Kogut N, Palmer J, Gaal K, Kim Y, Bhatia R, Yuan S, Kay C, Weiss L, Forman S. Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420 [Abstract] [Full Text] [Related]
29. Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells. Hicks ML, Lonial S, Langston A, Flowers C, Roback JD, Smith KJ, Mossavi Sai S, Teagarden D, Hamilton ES, Waller EK, Kaufman J. Transfusion; 2007 Apr; 47(4):629-35. PubMed ID: 17381621 [Abstract] [Full Text] [Related]
30. Improved Prediction of CD34+ Cell Yield before Peripheral Blood Hematopoietic Progenitor Cell Collection Using a Modified Target Value-Tailored Approach. Sheppard D, Tay J, Palmer D, Xenocostas A, Doulaverakis C, Huebsch L, McDiarmid S, Tinmouth A, Mallick R, Martin L, Birch P, Hamelin L, Allan D, Bredeson C. Biol Blood Marrow Transplant; 2016 Apr; 22(4):763-767. PubMed ID: 26643030 [Abstract] [Full Text] [Related]
31. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim. Weaver CH, Schulman KA, Buckner CD. Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117 [Abstract] [Full Text] [Related]
32. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, Westervelt P, Vij R, Abboud CN, Stockerl-Goldstein KE, Sempek DS, Smith AL, DiPersio JF. Biol Blood Marrow Transplant; 2008 Sep; 14(9):1045-1056. PubMed ID: 18721768 [Abstract] [Full Text] [Related]
33. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF. Engelhardt M, Winkler J, Waller C, Lange W, Mertelsmann R, Henschler R. Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898 [Abstract] [Full Text] [Related]
34. Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease. Copelan EA, Ceselski SK, Ezzone SA, Lasky LC, Penza SL, Bechtel TP, Klein JL, Hehmeyer DM, Scholl MD, Marshall DD, Elder PJ, Risley GL, Avalos BR. J Clin Oncol; 1997 Feb; 15(2):759-65. PubMed ID: 9053502 [Abstract] [Full Text] [Related]
35. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF. Lee JL, Kim S, Kim SW, Kim EK, Kim SB, Kang YK, Lee J, Kim MW, Park CJ, Chi HS, Huh J, Kim SH, Suh C. Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353 [Abstract] [Full Text] [Related]
36. Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study. Gazitt Y, Callander N, Freytes CO, Shaughnessy P, Liu Q, Tsai TW, Devore P. J Hematother Stem Cell Res; 2000 Oct; 9(5):737-48. PubMed ID: 11091498 [Abstract] [Full Text] [Related]
37. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, Nademanee A, McCarty J, Bridger G, Calandra G, 3101 Investigators. J Clin Oncol; 2009 Oct 01; 27(28):4767-73. PubMed ID: 19720922 [Abstract] [Full Text] [Related]
38. [Autologous peripheral blood stem cells mobilization with etoposide plus rhG-CSF versus cyclophosphamide plus rhG-CSF]. Shi YK, He XH, Han XH, Liu P, Yang JL, Zhou SY, Zhou AP, Zhang CG, Ai B. Ai Zheng; 2003 Dec 01; 22(12):1311-6. PubMed ID: 14693058 [Abstract] [Full Text] [Related]
39. Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis. Pettengell R, Morgenstern GR, Woll PJ, Chang J, Rowlands M, Young R, Radford JA, Scarffe JH, Testa NG, Crowther D. Blood; 1993 Dec 15; 82(12):3770-7. PubMed ID: 7505124 [Abstract] [Full Text] [Related]
40. Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation. Elayan MM, Horowitz JG, Magraner JM, Shaughnessy PJ, Bachier C. Biol Blood Marrow Transplant; 2015 Nov 15; 21(11):1921-5. PubMed ID: 26033279 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]